MBX Biosciences Inc. (MBX)
MBX trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026.
Profile
| Field | Value |
|---|---|
| Ticker | MBX on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | United States |
| IPO year | 2024 |
| SEC CIK | 0001776111 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | DE |
Financials
Not reported in SEC XBRL data.
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 10-Q 2026-11-09 |
| Cash and burn | $161.7M cash; operating cash flow -$24.0M a quarter. | Report 2026-09-30 |
| Shares outstanding | 49,656,265 (2026-11-05); 44,902,302 a year earlier. | Cover page 2026-11-05 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 1 S-3/F-3 shelf filings; 0 424B5 takedowns | Latest 2026-03-12 |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | Ernst & Young LLP, Indianapolis, Indiana, United States | PCAOB Form AP 2026-03-25 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $1.1M, sold $2.7M on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | Not filed | -$62.4M | -$34.9M | $161.7M | No debt tags | Needs four quarters | 10-Q 2026-11-09 |
| Q2 2026 2026-06-30 | Not filed | -$37.1M | -$22.6M | $54.1M | No debt tags | Needs four quarters | 10-Q 2026-11-09 |
| Q1 2026 2026-03-31 | Not filed | -$23.5M | -$20.2M | $45.2M | No debt tags | Needs four quarters | 10-Q 2026-11-09 |
| Q4 2025 2025-12-31 | Not filed | -$22.1M | -$18.3M | $75.3M | No debt tags | Needs four quarters | 10-Q 2026-11-09 |
| Q3 2025 2025-09-30 | Not filed | -$21.6M | -$21.5M | $223.1M | No debt tags | Needs four quarters | 10-Q 2026-11-09 |
| Q2 2025 2025-06-30 | Not filed | -$19.4M | -$17.4M | $39.8M | No debt tags | Needs four quarters | 10-Q 2026-11-09 |
| Q1 2025 2025-03-31 | Not filed | -$23.9M | -$22.7M | $29.9M | No debt tags | Needs four quarters | 10-Q 2026-11-09 |
| Q4 2024 2024-12-31 | Not filed | -$15.6M | -$16.0M | $49.4M | No debt tags | Needs four quarters | 10-K 2026-03-12 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | S-3ASR | 2026-03-12 |
| Latest annual report | 10-K | 2026-03-12 |
| Latest quarterly / interim | 10-Q | 2026-11-09 |
| Latest current report | 8-K | 2026-11-09 |
| Latest proxy | DEFA14A | 2026-05-08 |
Source: SEC EDGAR submissions feed, 238 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | +8.9% |
| 1 month | +14.2% |
| 3 months | -16.6% |
| Year to date | +77.4% |
| 1 year | +132.4% |
| From 52-week high | -20.9% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| ZLAB | Zai Lab Limited | $23.47 | -4.59% | $2.6B |
| XNCR | Xencor Inc. | $35.40 | -4.56% | $2.7B |
| HCM | HUTCHMED (China) Limited | $14.73 | -1.14% | $2.6B |
| VCRE | Vicore Pharma Holding AB | $10.16 | -1.93% | $2.9B |
| RCUS | Arcus Biosciences Inc. | $16.86 | -3.27% | $2.4B |
| IDYA | IDEAYA Biosciences Inc. | $30.36 | -4.62% | $2.9B |
| NAMS | NewAmsterdam Pharma Company N.V. | $19.46 | -3.38% | $2.3B |
| TLX | Telix Pharmaceuticals Limited | $8.92 | -3.36% | $3.0B |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier